Christopher Cannon

Research Narrative:

Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.

Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 18 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.

He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, and IMPROVE IT trials. Dr. Cannon serves as Executive Director of Cardiometabolic Trials at the Baim Institute for Clinical Research. He lead the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention.

Education:

• Columbia University, College of Physicians and Surgeons, 1986, MD
• Yale College, 1982, BA
• Other Professional Activities:
• Executive Director Cardiometabolic Trials, Harvard Clinical Research Institute

Publications (Pulled from Harvard Catalyst Profiles):

1. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 Mar 12; 139(11):1384-1395.

2. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019 Feb 21.

3. Contreras JP, Hong KN, Castillo J, Marzec LN, Hsu JC, Cannon CP, Yang S, Maddox TM. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. Clin Cardiol. 2019 Mar; 42(3):339-345.

4. Golwala H, Cannon CP, Bhatt DL. Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J. 2019 Jan 07; 40(2):218-219.

5. Fan W, Song Y, Inzucchi SE, Sperling L, Cannon CP, Arnold SV, Kosiborod M, Wong ND. Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes Obes Metab. 2019 Jan 04.

6. Ibrahim NE, Gaggin HK, Turchin A, Patel HK, Song Y, Trebnick A, Doros G, Maya JF, Cannon CP, Januzzi JL. Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. Eur Heart J Cardiovasc Pharmacother. 2019 01 01; 5(1):3-11.

7. Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes. 2019 Jan; 12(1):e005041.

8. Wang TY, Kaltenbach LA, Cannon CP, Fonarow GC, Choudhry NK, Henry TD, Cohen DJ, Bhandary D, Khan ND, Anstrom KJ, Peterson ED. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. JAMA. 2019 01 01; 321(1):44-55.

9. Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL, Scirica BM, Butler J, Cannon CP, Bhatt DL. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 Dec 25; 72(25):3370-3372.

10. Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol. 2018 Nov 14.